Skip to content
NHQualityCampaign.orgIndependent nursing home quality resource
Dementia CareFor families & professionals

National Partnership to Improve Dementia Care: Goals and Results

The National Partnership to Improve Dementia Care is a CMS initiative, launched in 2012, to cut unnecessary antipsychotic use in nursing homes. It also promotes person-centered care. CMS reports that long-stay antipsychotic use fell from 23.9% in late 2011 to 14.2% in mid-2025. This page summarizes its goals, results, critiques and its link to the earlier Advancing Excellence campaign. We are an independent site and are not affiliated with CMS or the Partnership.

Updated 6 min readHow we research
Two people reviewing reports and charts on laptops
Photo: Scott Graham (Unsplash License). Credits

Why did CMS launch the National Partnership?

By 2011 nearly one in four long-stay nursing home residents was receiving an antipsychotic, much of it off-label for behavioral symptoms of dementia despite FDA boxed warnings issued in 2005 and 2008. Federal reviews had raised concerns about off-label use and its cost. On May 30, 2012, CMS announced a partnership with federal and state agencies, nursing homes, other providers, advocacy groups and caregivers to improve dementia care and reduce unnecessary antipsychotics.

CMS describes the aims as enhancing quality of life for people living with dementia, protecting them from substandard care, promoting goal-directed, person-centered care for every resident, and increasing non-pharmacologic approaches. Archived campaign pages summarized the strategy in three words, "rethink, reconnect and restore": rethinking dementia care approaches, reconnecting with people through person-centered care, and restoring health and quality of life.

What were the Partnership goals, and were they met?

National Partnership goals and CMS-reported results (baseline Q4 2011 = 23.9%)
Year setGoalCMS-reported outcome
201215% reduction in long-stay antipsychotic use, originally targeted for the end of 2012Not met by end of 2012 (9.1% by Q1 2013); CMS reported the 15% goal exceeded by 2014, with a 17.1% drop by Q1 2014
201425% reduction by end of 2015; 30% by end of 2016CMS reported the 30% goal met: 34.1% reduction, to 15.7%, by Q1 2017
201715% reduction by end of 2019 for homes with high rates ("late adopters")Tracked in separate late-adopter data reports
OngoingContinued reduction where not clinically indicated40.6% reduction, to 14.2%, in Q2 2025 (MDS-based measure)

Every state improved. In its 2017 fact sheet CMS highlighted the District of Columbia (47.8%), Tennessee (43.5%), California (43%) and Arkansas (41.6%) as having the largest reductions. CMS has also said it "does not expect that the national prevalence of antipsychotic medication use will decrease to zero," because some residents have clear clinical indications.

2012
Partnership announced by CMS (May 30)
Source: CMS
15.7%
Long-stay antipsychotic use, Q1 2017
Source: CMS fact sheet
14.2%
Long-stay antipsychotic use, Q2 2025
Source: CMS data report

How did the National Partnership work?

  • Public reporting: facility antipsychotic rates on Nursing Home Compare (now Care Compare) and inclusion in the Five-Star quality rating.
  • State coalitions: dementia care coalitions in every state brought together providers, ombudsmen, surveyors and advocates.
  • Training: CMS's "Hand in Hand" dementia and abuse-prevention training series for nurse aides (Survey and Certification letter 12-44), plus surveyor training.
  • Survey focus: revised interpretive guidance and focused dementia care surveys.
  • Technical help: Quality Improvement Organizations (now QIN-QIOs) worked directly with nursing homes.
  • Research: studies on care systems, individualized dementia care and telepsychiatry for rural homes.

Did the Partnership expand to other psychotropic drugs?

CMS's 2014 fact sheet said the Partnership aimed to reduce "other potentially harmful medications" too, and that CMS was watching for shifts toward anti-anxiety drugs and sedative-hypnotics. Independent research later found some substitution: an analysis of Medicare data from 2009 to 2014 found mood stabilizer use rose after the Partnership began, and a follow-up study linked much of that growth to gabapentin. Federal rules on psychotropics, now surveyed under F605, cover all drugs that affect mental processes and behavior, not only antipsychotics. The practical lesson for nursing homes: track all psychotropics, not just the measured one. Our antipsychotic reduction page covers the current rules.

How did the Partnership relate to the Advancing Excellence campaign?

Advancing Excellence in America's Nursing Homes was a separate, voluntary national quality campaign launched in 2006 that used this web address until about 2018. According to archived versions of its site, the campaign "offered to make available a variety of resources and clinical tools to assist nursing homes achieve the goals of this partnership," including pages for people living with dementia, families and professionals. Its Medications goal, the original campaign said, would "initially ... focus on antipsychotic drugs," giving staff non-drug alternatives and medication reconciliation tools.

This site is not that campaign and is not affiliated with it or its successor organization. For the full story, see our history of the Advancing Excellence campaign.

What are the criticisms of the Partnership?

  • Slower than announced: the first 15% goal was originally set for the end of 2012 and was reached later than planned.
  • Measurement gaps: a 2021 HHS OIG report found the MDS-based measure under-counted antipsychotic use; CMS responded with the hybrid measure in January 2026.
  • Diagnosis gaming: CMS's own memo QSO-23-05-NH cited erroneous schizophrenia coding that can mask antipsychotic use, and launched audits.
  • Substitution: rising use of other sedating drugs in some studies suggests a single-drug measure is not enough.
  • Advocate concerns: some consumer groups argue that progress has stalled and that informed consent was under-enforced before the 2025 guidance changes.

What does this mean for nursing homes and families today?

The Partnership's core message holds: most distress in dementia can be prevented or eased without antipsychotics, and when drugs are used they need a clear reason, consent and regular review. Families can use the family guide to ask the right questions. Teams can start with the professional toolkit and their QAPI program. Back to the dementia care guide.

Frequently asked questions

What is the National Partnership to Improve Dementia Care in Nursing Homes?

It is a CMS-led initiative announced on May 30, 2012, that brings together federal and state agencies, nursing homes, professional groups, advocates and families. Its aims are better quality of life for people living with dementia, protection from substandard care, person-centered care and less use of antipsychotics when they are not clinically indicated.

Did the National Partnership reduce antipsychotic use?

Yes, according to CMS. Long-stay antipsychotic use fell from 23.9% at the end of 2011 to 15.7% in early 2017, meeting the 30% reduction goal, and to 14.2% by mid-2025, a 40.6% drop. Researchers note some shift toward other psychotropic drugs, and CMS changed the measure in 2026 to capture use more accurately.

What was the original goal of the National Partnership?

The first goal, announced in 2012, was to reduce antipsychotic use among long-stay nursing home residents by 15%, originally by the end of 2012. CMS reported exceeding it by 2014 and then set goals of 25% by the end of 2015 and 30% by the end of 2016, which it reported meeting in 2017.

Is the National Partnership the same as Advancing Excellence?

No. The National Partnership is a CMS initiative begun in 2012. Advancing Excellence in America's Nursing Homes was a separate voluntary quality campaign begun in 2006 that offered resources supporting the Partnership's goals. This website is independent and is not affiliated with either.

What is Hand in Hand dementia training?

Hand in Hand is a CMS training series for nursing home nurse aides on person-centered dementia care and abuse prevention, released in connection with the National Partnership (Survey and Certification letter 12-44). Nursing homes can use it toward federal requirements for dementia management and abuse-prevention training.

Free, no-obligation help

Get help choosing care or coverage

Talk with a licensed agent about Medicare, Medigap, Medicare Advantage and ways to pay for a nursing home stay. Or call 1-800-MEDIGAP (1-800-633-4427).

Answered by licensed insurance agents, not by Medicare or CMS.

Sources

  1. CMS: National Partnership to Improve Dementia Care in Nursing Homes
  2. CMS press release (May 30, 2012): CMS announces partnership to improve dementia care in nursing homes
  3. CMS fact sheet (Sept 19, 2014): National Partnership exceeds goal, sets new goals
  4. CMS fact sheet (Oct 2, 2017): National Partnership achieves goal to reduce unnecessary antipsychotics
  5. CMS: Antipsychotic Medication Use Data Report (2025 Q2 data)
  6. HHS OIG (2021): CMS could improve the data it uses to monitor antipsychotic drugs in nursing homes

Medical disclaimer. This page is general education, not medical, legal or financial advice, and it does not replace the judgment of a qualified clinician who knows the resident. Do not start, stop or change any medication without talking to the prescriber. In an emergency, call 911.

Independent resource. NHQualityCampaign.org is an independent educational resource. It is not affiliated with, endorsed by or operated by the Centers for Medicare & Medicaid Services (CMS), the U.S. Department of Health and Human Services (HHS), any government agency, or the original Advancing Excellence in America’s Nursing Homes campaign or its sponsors. Historical campaign information is summarized with attribution for educational purposes.